Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB/II Multi-Cohort Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

Next Previous
X
Search
Trial Profile

A Phase IB/II Multi-Cohort Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Letrozole (Primary) ; Talazoparib (Primary) ; Tiragolumab (Primary) ; Trastuzumab emtansine (Primary)
  • Indications Carcinoma; Endometrial cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms AFT-50 EndoMAP; EndoMAP

    • Most Recent Events

    • 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 17 Oct 2023 The protocol has been amended to addition to Number of Arms 6 to 7 with change in study population 148.
    • 17 Oct 2023 Planned number of patients changed from 124 to 148.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top